Agoracom: Small Cap Investment - Resverlogix Corp.

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Ya never know

in response to

Ya never know

chicagoest

posted on Apr 11, 2020 07:53AM

chicagoest thank you for that piece of information.

However Resverlogix in their March 23, 2020 news release state that "apabetalone treatment may potentially reduce viral entry into cells, and limit virus particles’ ability to replicate", noting that as stated in the news release that it may not will reduce viral entry into cells. (bolding added)

"In a recent New York Times article published on March 17th, 2020, researchers at the Quantitative Biosciences Institute Coronavirus Research Group, University of California, San Francisco, identified the human bromodomain-containing protein (BRD2) – a direct target of apabetalone – as a critical interaction partner for SARS-CoV-2. Publications are pending. BRD2 binds to the E (envelope) protein of the virus particles and is believed to participate in the viral reproduction process. Furthermore, apabetalone is known to inhibit expression of Angiotensin-converting enzyme 2 (ACE2), the receptor utilized by the novel coronavirus particles to gain entry into human cells. Together, these observations suggest apabetalone treatment may potentially reduce viral entry into cells, and limit virus particles’ ability to replicate." (bolding added)

I asked RVX IR to clarify but have not done so to date.

Koo

6 Recommendations

Apr 11, 2020 09:02AM

Apr 11, 2020 09:08AM

Back To Forum List View

Please to post a reply